|
Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome Clinical research trials and Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome. Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome clinical trial. Human subjects often receive the most effective healthcare possible for their Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome  Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome
Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome
For Condition: secondary myelodysplastic syndromes,de novo myelodysplastic syndromes,refractory anemia with excess blasts,refractory anemia with excess blasts in transformation
Status: No longer recruiting
Sponsor(s): ALZA ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combining topotecan and cytarabine given with amifostine in treating patients who have myelodysplastic syndrome.
Details: OBJECTIVES: I. Determine the toxic effects of amifostine, topotecan, and cytarabine in patients with poor risk myelodysplastic syndrome. II. Determine the hematologic response rate, cytogenetic response rate, and the rate of polyclonal hematopoiesis following this treatment regimen. III. Determine the duration of response and time to disease progression following this treatment regimen in these patients. PROTOCOL OUTLINE: Patients receive topotecan by continuous IV over 24 hours plus cytarabine IV over 2 hours, on days 1-5. Patients receive amifostine IV over 15 minutes every other day for a maximum of 60 days. Patients may receive a second course of the same regimen 8 weeks after the first. Patients are followed at least monthly for 2 years, then every 3-6 months until death. PROJECTED ACCRUAL: Approximately 25 patients will be accrued for this study within 1 to 1.5 years.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: 16 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed poor risk myelodysplastic syndrome, including at least one of the following: Bilineage cytopenia; Unfavorable cytogenetic abnormalities; Refractory anemia with excess blasts and/or refractory anemia with excess blast in transformation (greater than 5% blast) - At least 0.5 on the International Prognostic Score System - No chronic myelomonocytic leukemia - No hypocellular myelodysplastic syndrome (marrow cellularity less than 30%) --Prior/Concurrent Therapy-- - Biologic therapy: No prior blood or bone marrow transplantations - Chemotherapy: No prior acute myeloid leukemia chemotherapy (except hydroxyurea or low dose cytarabine); No prior topotecan; No prior amifostine - Endocrine therapy: Not specified - Radiotherapy: Not specified - Surgery: Not specified - Other: At least 24 hours since prior antihypertensive medication prior to amifostine --Patient Characteristics-- - Age: 16 and over - Performance status: ECOG 0-1 - Life expectancy: Not specified - Hematopoietic: Absolute neutrophil count less than 1,500/mm3; Platelet count less than 100,000/mm3; Hemoglobin less than 10 g/dL - Hepatic: ALT less than 5 times upper limit of normal - Renal: Creatinine no greater than 1.4 mg/dL - Cardiovascular: No congestive heart failure - Other: Not pregnant or nursing; Fertile patients must use effective contraception; Must have right atrial catheter inserted
Total Enrollment:
Location and Contact Information:
Overall Study Official:
HenryFung, Study Chair, ALZA
Cancer Center and Beckman Research Institute, City of Hope
Duarte, California, 91010-3000
United States
Additional Information:
Study ID Numbers: CDR0000066982; CHNMC-IRB-98056,NCI-V99-1533,ALZA-CHNMC-IRB-98056
Study Start Date: January 1999
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003827
Other Secondary Myelodysplastic Syndromes Studies:
1. Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome
2. Daclizumab Compared With Antithymocyte Globulin in Treating Cytopenia in Patients With Myelodysplastic Syndromes
3. Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia
4. Low-Dose Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Allogeneic Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorder or Myelodysplastic Syndrome
5. Infliximab in Treating Patients With Myelodysplastic Syndrome
Related Studies:
Other secondary myelodysplastic syndromes Clinical Trials
Other California Clinical Trials
Other Duarte Clinical Trials
Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome
|
|
|
|
|
|
|
|
